Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Current Medicinal Chemistry|March 23, 2004
Computational and experimental studies on human misshapen/NIK-related kinase MINK-1Kunbin Qu, Yanmei Lu, Nan Lin, et al.
Immunity|February 5, 2002
Activation of the PKB/AKT pathway by ICAM-2Omar D Perez, Shigemi Kinoshita, Yasumichi Hitoshi, et al.
Methods in Enzymology|December 13, 2005
A homogeneous FRET assay system for multiubiquitin chain assembly and disassemblyTarikere L Gururaja, Todd R Pray, Raymond Lowe, et al.
Drug Discovery Today|August 29, 2003
Drug discovery in the ubiquitin regulatory pathwayBrian R Wong, Francesco Parlati, Kunbin Qu, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|February 12, 2016
Janus kinase inhibition prevents cancer- and myocardial infarction-mediated diaphragm muscle weakness in miceIra J Smith, Brandon Roberts, Adam Beharry, et al.
ACS Medicinal Chemistry Letters|November 17, 2022
Optimization of Pyrimidine Compounds as Potent JAK1 Inhibitors and the Discovery of R507 as a Clinical CandidateYan Chen, Hui Li, Rose Yen, et al.
Bioorganic & Medicinal Chemistry Letters|April 15, 2017
Developing DYRK inhibitors derived from the meridianins as a means of increasing levels of NFAT in the nucleusSimon J Shaw, Dane A Goff, Nan Lin, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|January 18, 2003
Cell cycle regulatory E3 ubiquitin ligases as anticancer targetsTodd R Pray, Francesco Parlati, Jianing Huang, et al.
The Journal of Biological Chemistry|October 8, 2004
Identification and functional characterization of a novel human misshapen/Nck interacting kinase-related kinase, hMINK betaYuanming Hu, Cindy Leo, Simon Yu, et al.
Clinical Immunology (Orlando, Fla.)|June 1, 2007
Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitorPolly R Pine, Betty Chang, Nathan Schoettler, et al.
Pageof 5